CVD researcher/clinician named Editor-in-Chief of Circulation: Genomic and Precision Medicine
'Dr. Ahmad's extensive cardiology expertise and leadership in the field of cardiovascular genomics, his commitment to innovation and drive for scientific advances will guide Circulation: Genomic and Precision Medicine to new heights as the specialty continues to evolve,' said Eldrin F. Lewis, M.D., M.P.H., FAHA, volunteer chair of the American Heart Association's Scientific Publishing Committee, which oversees the Association's 14 peer-reviewed scientific journals. Lewis is the Simon H. Stertzer, M.D., Professor of Cardiovascular Medicine and chief of the division of cardiovascular medicine at Stanford University in Stanford, California.
Ahmad most recently served as an associate editor and senior associate editor of the Journal of the American Heart Association (JAHA) for the past 10 years. He stepped down from JAHA to assume his new role with Circulation: Genomic and Precision Medicine. 'Thank you to Dr. Ahmad for his integral role in advancing JAHA's impact and reputation for scientific excellence over the last decade,' said Lewis.
Ahmad's additional roles at the University of Iowa include associate professor of molecular physiology and biophysics, associate professor of radiology and director of the Cardiovascular Disease Fellowship Training Program. He also leads a laboratory conducting basic and translational research into the genetic and genomic mechanisms underlying inherited cardiovascular disorders, including hypertrophic cardiomyopathy, dilated cardiomyopathy, glycogen storage cardiomyopathy, inherited arrhythmias and pulmonary hypertension, and the mechanisms by which the SGLT1 protein contributes to heritable and acquired heart failure. Ahmad's clinical expertise includes coronary artery disease, cardiomyopathy and other inherited cardiovascular conditions, and he continues to mentor countless postdoctoral fellows and medical, graduate and undergraduate students.
'Cardiovascular genetics combined with genomics is a quickly evolving field that is highly dependent on the contributions of many professionals from various disciplines, and advances are emerging quickly,' said Ahmad. 'In my new role as editor-in-chief, I am excited to build on the journal's success while elevating the inclusion of studies that advance implementation science, community-engaged/community-based participatory research, as well as papers highlighting equitable health and social drivers of health. These are critical areas to understanding the genetic and genomic basis of cardiovascular and cerebrovascular disease. Translating these findings to practice is key to improving care and outcomes for patients,' said Ahmad.
Ahmad also plans to champion initiatives that strengthen the journal's position within the specialty, such as:
Ahmad earned his doctor of medicine degree at McGill University in Montreal, Canada, followed by postgraduate clinical training at McGill University, Baylor College of Medicine in Houston and the Brigham and Women's Hospital in Boston. He subsequently earned a Ph.D. in human genetics from Baylor College of Medicine and completed a Howard Hughes Medical Institute postdoctoral fellowship in mouse genetics at Harvard Medical School.
In addition to his role with JAHA, Ahmad has served in several leadership roles in the American Heart Association's Council on Genomic and Precision Medicine, the Council on Epidemiology and Prevention, and the Committee for Scientific Sessions Programming. He also serves on the Association's Hypertrophic Cardiomyopathy Science Advisory Group.
Ahmad has received numerous research grants and is active in several clinical trials of novel therapies for heritable cardiomyopathies. He has co-authored more than 60 published, peer-reviewed research articles including serving as the chair of the writing group for the 2019 American Heart Association Scientific Statement, " Establishment of Specialized Clinical Cardiovascular Genetics Programs: Recognizing the Need and Meeting Standards.' He also authored the chapter on cardiovascular genetics in the American College of Cardiology Self-Assessment Program (ACCSAP).
Circulation: Genomic and Precision Medicine, which launched in 2008, is the leading scientific journal for original research detailing mechanistic, diagnostic, prognostic and therapeutic advances in genetics and genomics, including studies in human subjects, laboratory animals, in vitro and in silico, focused on relevance to human cardiovascular biology and disease. Areas of interest include investigations of clinical genetics as applied to cardiovascular disorders, the molecular basis of complex cardiovascular disorders, and novel applications of precision medicine. The online-only journal publishes six issues per year, and accepted articles are published online ahead of issue.
Circulation: Genomic and Precision Medicine is part of the American Heart Association's portfolio of 14 peer-reviewed scientific journals: Circulation; Stroke; Hypertension; Journal of the American Heart Association; Arteriosclerosis, Thrombosis, and Vascular Biology; Circulation Research; Circulation: Arrhythmia and Electrophysiology; Circulation: Heart Failure; Circulation: Cardiovascular Imaging; Circulation: Cardiovascular Interventions; Circulation: Cardiovascular Quality and Outcomes; Stroke: Vascular and Interventional Neurology; and Annals of Internal Medicine: Clinical Cases. Each journal is editorially independent of one another and the Association in support of open dialogue and discourse, which are essential to the dynamic nature of scientific discovery. Editors-in-chief are selected by the Association's volunteer-led Scientific Publishing Committee, and each editor-in-chief assembles and manages the editorial board, vision and strategy for their journal. The Association is the publisher of the journals; however, the Association has no oversight on the science content published.
Studies published in the American Heart Association's scientific journals are peer-reviewed. The statements and conclusions in each manuscript are solely those of the study authors and do not necessarily reflect the Association's policy or position. The Association makes no representation or guarantee as to their accuracy or reliability.
The Association receives more than 85% of its revenue from sources other than corporations. These sources include contributions from individuals, foundations and estates, as well as investment earnings and revenue from the sale of our educational materials. Corporations (including pharmaceutical, device manufacturers and other companies) also make donations to the Association. The Association has strict policies to prevent any donations from influencing its science content. Overall financial information is available here.
Additional Resources:
###
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public's health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy and care, we work tirelessly to advance health and transform lives every day. Connect with us on heart.org, Facebook, X or by calling 1-800-AHA-USA1.
For Media Inquiries: 214-706-1173
Michelle Kirkwood: [email protected]
For Public Inquiries: 1-800-AHA-USA1 (242-8721)
heart.org and stroke.org
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 hours ago
- Yahoo
IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event
SOUTH SAN FRANCISCO, Calif., July 21, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations event. 2025 BTIG Virtual Biotechnology ConferenceTuesday, July 29th, 2025 at 4:40 PM ET Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Justin Zelin, Director, Biotechnology Research Analyst A live audio webcast of the conference event, as permitted by the conference host, will be available at the "Investors/Events" section of the IDEAYA website at and/or through the conference host. A replay of available webcasts will be accessible for 30 days following the live event. About IDEAYA Biosciences IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies to address unmet medical needs in cancer. The company integrates small molecule drug discovery, structural biology and bioinformatics with extensive capabilities in identifying and validating translational biomarkers to develop potentially first-in-class targeted therapies for selected patient populations. IDEAYA has built a robust pipeline of targeted therapies focused on synthetic lethality and antibody-drug conjugates, or ADCs, including bispecifics, with the goal of improving clinical outcomes for patients with cancer. Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K filed on February 18, 2025. Investor and Media ContactIDEAYA BiosciencesJoshua Bleharski, Financial Officerinvestor@ View original content to download multimedia: SOURCE IDEAYA Biosciences, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Yahoo
Favorable Government Support Fuels Germany's Biotech Innovation and Commercialization: Market to Surpass USD 94 Billion by 2034 Led by QIAGEN, Thermo Fisher Scientific, Illumina and Roche
German Biotechnology Market Dublin, July 18, 2025 (GLOBE NEWSWIRE) -- The "Germany Biotechnology Market Report and Forecast 2025-2034" has been added to Germany biotechnology market was valued at USD 35.30 Billion in 2024, bolstered by robust public and private investment in biotech innovation, alongside significant R&D endeavors supported by established academic and research institutions. The market is expected to grow at a CAGR of 10.30% during 2025-2034, potentially reaching USD 94.09 Billion by 2034. Government initiatives and funding play a critical role in accelerating the development and commercialization of advanced biotechnological solutions, contributing to market expansion. This growth is also underpinned by strong infrastructure, substantial R&D capabilities, and a skilled workforce. The increasing adoption of precision medicine and biopharmaceuticals is anticipated to further drive market growth in the forecast period. Increasing Prevalence of Chronic Diseases The market's growth is heavily influenced by the rising incidence of chronic and degenerative diseases. According to WHO data from 2021, conditions such as ischemic heart disease, Alzheimer's disease, stroke, various cancers, COPD, and kidney disorders impose a significant health burden, intensifying demand for innovative diagnostics, targeted therapies, and precision medicine. This drives forward the biotechnology sector, bolstered by increased research and development investments from both public and private sectors. Germany Biotechnology Market Trends Key trends include rising investments and the advent of cutting-edge, sustainable technologies. Investment confidence continues to grow, evidenced by a 78% increase in funding for German biotech firms, reaching EUR 1.917 billion in 2024, according to BIO Deutschland and EY. This capital influx is set to enhance market growth and technological progress. Additionally, innovative, eco-friendly food technologies are driving demand. In March 2024, the launch of Kynda's zero-waste mycelium-based food product in Germany highlighted a move towards sustainable consumer solutions, anticipating an increase in the market's growth and the adoption of sustainable biotech products. Germany Biotechnology Market Segmentation The market analysis includes segments such as: Product Type: Instruments, Reagents, Software and Services, Others Technology: Nanobiotechnology, Tissue Engineering, DNA Sequencing, Cell-based Assays, Fermentation, PCR Technology, Chromatography, Others Application: Health, Food & Agriculture, Natural Resources & Environment, Industrial Processing, Bioinformatics, Others Germany Biotechnology Market Share: DNA Sequencing's Impact The biotechnology market in Germany is diversified across various technologies, with DNA sequencing anticipated to lead. Innovations like Merck's Aptegra platform, which integrates multiple assays into one, significantly reduce testing times and costs, driving DNA sequencing's important role in the market's future growth. Leading Players in the Germany Biotechnology Market The major market players include: QIAGEN N.V: Expanded its portfolio by acquiring Genoox, enhancing AI-driven genetic data interpretation for clinical decision-making. Thermo Fisher Scientific, Inc: Introduced sustainable centrifuges in Germany, boosting energy efficiency in bioprocessing. Illumina Inc: Partnered with to launch an extensive clinical multiomic dataset, propelling advancements in metabolic disease therapies. F. Hoffman-La Roche Ltd: Gained FDA clearance for a dual mRNA probe assay improving B-cell lymphoma diagnostics. Other key companies include Evotec SE, Bio-Rad Laboratories, Agilent Technologies, and BioNTech SE. Key Questions Answered What was the Germany biotechnology market value in 2024? What is the forecast for 2025-2034? What drives demand in the market? How has the market performed historically, and future expectations? What are the major trends and challenges? Which product, technology, and application segments are expected to dominate? Who are the key players? Key Attributes Report Attribute Details No. of Pages 250 Forecast Period 2025-2034 Estimated Market Value (USD) in 2025 $35.3 Billion Forecasted Market Value (USD) by 2034 $94.09 Billion Compound Annual Growth Rate 10.3% Regions Covered Germany Key Topics Covered 1 Preface 1.1 Objectives of the Study 1.2 Key Assumptions 1.3 Report Coverage - Key Segmentation and Scope 1.4 Research Methodology 2 Executive Summary 3 Biotechnology Market Overview 3.1 Europe Biotechnology Market 3.2 Germany Biotechnology Market 4 Vendor Positioning Analysis 4.1 Key Vendors 4.2 Prospective Leaders 4.3 Niche Leaders 4.4 Disruptors 5 Germany Biotechnology Market Landscape 5.1 Germany Biotechnology Market: Developers Landscape 5.2 Germany Biotechnology Market: Product Landscape 6 Germany Biotechnology Market Dynamics 6.1 Market Drivers and Constraints 6.2 SWOT Analysis 6.3 PESTEL Analysis 6.4 Porter's Five Forces Model 6.5 Key Demand Indicators 6.6 Key Price Indicators 6.7 Industry Events, Initiatives, and Trends 6.8 Value Chain Analysis 7 Germany Biotechnology Market Segmentation (2018-2034) 7.1 By Product Type 7.2 By Technology 7.3 By Application 8 Regulatory Framework 9 Patent Analysis 10 Funding and Investment Analysis 11 Strategic Initiatives 12 Supplier Landscape 13 Germany Biotechnology Market - Distribution Model (Additional Insight) 14 Key Opinion Leaders (KOL) Insights (Additional Insight) For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment German Biotechnology Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Fast Company
4 days ago
- Fast Company
The next frontier for precision medicine: Pediatricians
Many families now have a new reality when they visit their pediatrician's office. Instead of leaving with more questions, they have answers and a real plan. Genomic testing, once reserved for rare or complex cases and ordered by specialists, is rapidly becoming a standard tool in pediatric care. The latest guidance from the American Academy of Pediatrics (AAP), released this year, recommends using exome and genome sequencing as a first-tier test for more children, particularly those with developmental delays and intellectual disabilities. More than one in three children with developmental delays, intellectual disabilities, or autism have an underlying genetic condition that can be found using genetic testing. Given known genetic links to autism, pediatricians can now genomic insights right from the start, moving forward bringing answers and actionable next steps in a child's care journey. This shift is transforming how we diagnose, treat, and support kids with unexplained medical challenges. Invest in science Spun out of the National Institutes of Health (NIH), GeneDx was founded 25 years ago on the belief that genomic science could fundamentally change how we diagnose and treat disease. At the time, this field felt like the frontier, a promising but distant future, more exploration than clinical applications. Today, that vision is a reality. GeneDx has discovered more than 500 links between specific genes and diseases. What once felt futuristic is now central to modern pediatric care. Genomic testing has become faster, more affordable, and more accessible. The updated AAP guidance means genomic testing should be integrated into every family's pediatric office. It should be used to diagnose rare diseases and understand the genetic cause of common conditions like autism and epilepsy with greater speed and precision. It's not just about understanding the root cause, it's about accelerating the path to accurate treatment that can change or save children's lives. This transformation didn't happen overnight. It was the result of decades of scientific investment—our collective bet on the future of healthcare—to one day ensure children live longer and healthier lives. That investment paid off. Genomic testing not only improves outcomes for patients and families, but it also reduces overall healthcare costs through fewer unnecessary tests and procedures, earlier diagnoses, and more targeted interventions and treatments. Continued investments in science and medicine are essential. Advancing access to genomic testing isn't just about what's possible today, it's about building a healthcare system that's smarter, more sustainable, and truly patient-centered. Why genomic testing matters What was once only available to few, is now broadly available. Genomic testing offers immediate and profound benefits for families. For children facing developmental delays or other unexplained health issues, a single test can sometimes reveal the underlying cause in weeks or even days, in critical situations. This means families no longer must endure months or sometimes years of uncertainty—with multiple rounds of inconclusive tests, uninformative specialist visits, or unnecessary medical bills and suffering. Instead, clear answers can arrive quickly, allowing everyone to move forward with personalized treatment plans in confidence. With a genetic diagnosis in hand, doctors can provide truly targeted care, tailoring treatments, therapies, and support to fit the unique needs for a diagnosis and in some cases, even stop disease progression. A confirmed diagnosis also opens doors to early intervention, specialized care teams, clinical trials, and support networks that might otherwise remain out of reach. Exome and genome testing are transforming the path to answers and support for children and their families, and now it's more accessible than ever before. Looking ahead We see the AAP's guidance as a major milestone, bringing genomics into everyday pediatric care. And for the first time, genomics is equipping pediatricians with critical insights to support early diagnosis and intervention. But this is just the beginning. We're still in the early chapters of what genomic science and care can unlock. To fully realize its potential, we must continue investing in innovation and driving progress that elevates the standard of care across every clinical setting. Where a child accesses care should never determine their outcome. Today, we see genomic insights shaping the future in pediatricians' offices. Tomorrow, we envision a world where every baby's genome is sequenced at birth, giving families the power to stop disease before symptoms even start. My career has been dedicated to expanding access to genomic testing, and I commend the AAP for helping pave the way toward a new standard of care, one where genomics plays a central role in improving pediatric health outcomes nationwide. The path to answers—and to hope—has never been more accessible. Bringing genomics into the hands of every pediatrician marks a critical step toward shortening the diagnostic journey for families, enabling earlier intervention, and reducing costs for both patients and the healthcare system. It's a meaningful advancement in pediatric care, and one that brings us closer to a future where children can be diagnosed before symptoms even begin.
